Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 4/20 | 0.59 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.57 |
| ▸ | LTA4H | P09960 | 2/20 | 0.54 |
| ▸ | CSK | P41240 | 1/20 | 0.51 |
| ▸ | LNPEP | Q9UIQ6 | 2/20 | 0.51 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.50 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | CA12 | O43570 | 1/20 | 0.48 |
| ▸ | CA1 | P00915 | 1/20 | 0.48 |
| ▸ | CA2 | P00918 | 1/20 | 0.48 |
| ▸ | CA7 | P43166 | 1/20 | 0.48 |
| ▸ | CA9 | Q16790 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4933164 | 1.00 | FFAR1 (0.59) | FFAR1HDAC8LTA4HCSKLNPEP | |
| SCHEMBL27386689 | 0.86 | LTA4H (0.65) | FFAR1HDAC8LTA4HLNPEP | |
| SCHEMBL27699155 | 0.86 | ITGB3 (0.66) | FFAR1LTA4HITGB3ITGA2BNPC1 | |
| SCHEMBL1803032 | 0.83 | ALPI (0.66) | HDAC8LTA4HCSK | |
| SCHEMBL2512478 | 0.83 | ALPI (0.66) | HDAC8LTA4HCSK | |
| SCHEMBL1168389 | 0.83 | ALPI (0.66) | HDAC8LTA4HCSK | |
| SCHEMBL4927924 | 0.82 | CSK (0.55) | HDAC8CSKITGB3ITGA2B | |
| SCHEMBL4927914 | 0.82 | CSK (0.55) | HDAC8CSKITGB3ITGA2B | |
| SCHEMBL4930673 | 0.82 | KDM4E (0.58) | HDAC8CSKITGB3ITGA2B | |
| SCHEMBL4930679 | 0.82 | KDM4E (0.58) | HDAC8CSKITGB3ITGA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080132539-A1 | Hydroxamic Acid Derivative And Age Generation Inhibitor Containing The Derivative | KUREHA CORPORATION (JP) | 2008-06-05 | — | — | US | disclosed |
| EP-1707560-A1 | HYDROXAMIC ACID DERIVATIVE AND AGE GENERATION INHIBITOR CONTAINING THE DERIVATIVE | Kureha Corporation (JP) | 2006-10-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080132539-A1 | Hydroxamic Acid Derivative And Age Generation Inhibitor Containing The Derivative | HDAC5, HDAC1, HDAC9 | FFAR1 3533/4885HDAC8 4/4885LTA4H 1552/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.